Comprehensive guides with safety triggers, contrarian views, research gaps, and practical protocol references.
DSIP was named for inducing delta sleep, but independent labs failed to replicate that in humans, no one has found its receptor or gene, and its best human stress trial found zero effect. Fascinating biology, unproven clinically.
DSIP (Delta Sleep-Inducing Peptide / Emideltide) is a nonapeptide studied for sleep, stress, and opioid withdrawal. Its human sleep data is inconsistent, its receptor is unknown, rodent stress effects failed to translate to humans, and it is not FDA-approved, with a PCAC review set for July 2026.
Cerebrolysin is a porcine-brain peptide mixture sold as a master key for brain repair. It has decades of human trials, approval in 50+ countries, no FDA approval, and a Cochrane safety signal that complicates the story.
Cerebrolysin is a porcine-derived neurotrophic peptide preparation studied for stroke, TBI, and dementia. Human RCT data exists but is heterogeneous and industry-weighted, independent Cochrane reviews find no mortality benefit and a serious-adverse-event signal, and it is not FDA-approved.
KPV is the three-amino-acid tail of alpha-MSH: it keeps the parent hormone's anti-inflammatory power, drops the pigmentation, and targets inflamed tissue through the PepT1 transporter. The catch: every result so far is from cells or animals.
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory, antimicrobial, gut, and skin applications. Evidence is entirely preclinical, with no completed human trials, and the compound is under FDA PCAC review for July 2026.
A 16-amino-acid fragment of human growth hormone engineered to trigger fat metabolism without activating the GH receptor, AOD-9604 cleared early clinical trials for obesity before its pivotal Phase IIb collapsed under a placebo response. Now stripped of FDA Category 2 status and banned by WADA, its most interesting data may be in a direction nobody expected: cartilage repair.
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176-191 of human growth hormone, with an added N-terminal tyrosine. It selectively activates beta-3 adrenergic receptors to stimulate lipolysis without engaging the GH receptor, producing no measurable effect on IGF-1 or glucose. Its Phase IIb obesity trial (OPTIONS, 536 participants) was terminated in 2007 when placebo outperformed expectations. Preclinical cartilage regeneration data has since repositioned the compound toward joint repair, but no human joint trial exists.
The oral compound that reliably raises GH and IGF-1 to youthful levels, delivers measurable gains in lean mass and sleep architecture, yet consistently failed to translate those biomarker wins into functional outcomes across 30 years of clinical trials.
MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue that selectively agonises the ghrelin receptor (GHS-R1a). It increases 24-hour GH secretion by up to 97% and IGF-1 by 60-79%, producing verified gains in fat-free mass and sleep quality. However, the lean mass does not translate to strength, the bone turnover does not translate to density, and insulin resistance is a consistent pharmacological cost.
The first FDA-approved peptide that targets the brain's desire circuitry instead of the body's vascular hardware, opening a new front in sexual medicine, appetite regulation, and central neuromodulation.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and centrally acting melanocortin receptor agonist FDA-approved for premenopausal female HSDD. It bypasses peripheral blood flow entirely, activating MC3R and MC4R in the hypothalamus to trigger dopamine and oxytocin release. Emerging data positions it as a post-GLP-1 weight rebound shield and a rescue therapy for PDE5 inhibitor non-responders in men.
The first dual-action incretin that outpaces single-agonist therapy across weight, glucose, heart failure, and sleep apnoea, while forcing medicine to reckon with the musculoskeletal cost of rapid metabolic transformation.
Tirzepatide is an imbalanced dual GIP/GLP-1 receptor agonist achieving 15-22.5% body weight reduction, HbA1c cuts of up to 2.6%, FDA approval for sleep apnoea, and a 38% reduction in heart failure events. Its biased agonism at the GLP-1 receptor avoids receptor desensitisation, but rapid weight loss raises real concerns about bone density and lean mass.
The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.
Semaglutide is a modified GLP-1 analogue with a ~1-week half-life, proven to reduce body weight by 10-17%, cut cardiovascular events by 20%, resolve fatty liver disease, and slow kidney decline. Its reach now extends into addiction, sleep apnea, and neuroinflammation.
An 11-amino-acid peptide derived from erythropoietin's helix-B surface that selectively activates the Innate Repair Receptor, triggering nerve regeneration and tissue protection without the blood-thickening risks of EPO.
ARA-290 isolates the tissue-repair signal from erythropoietin without stimulating red blood cell production. Phase II trials showed a 23% increase in corneal nerve fiber area in sarcoidosis patients, proving structural nerve regeneration rather than symptomatic relief. The molecule also improved HbA1c and lipid profiles in diabetic trials, with effects lasting weeks beyond the final dose.
The best immune peptides aren't the ones that turn the system up. They're the ones that teach it when to hold still.
Immune regulation is about homeostasis, not amplification. Thymosin Alpha-1 acts as a thermostat — pushing Th1 when the system is under-responsive, pushing T-regs when it's over-firing. Bioregulators work upstream at the level of gene expression. Thymosin Beta-4 regenerates across organ systems. Selank bridges the brain-immune axis. Understanding when to use each — and when not to — is the difference between peptide therapy and peptide tourism.
Cardiac peptide therapy isn't science fiction — Tβ4 has completed Phase 2 in acute MI (NCT05984134), and SS-31 sits in advanced-phase trials for mitochondrial heart disease.
A plain-English look at the peptides being investigated for cardiovascular repair — Thymosin β4 for post-infarct tissue regeneration, elamipretide for mitochondrial membrane stability, and the adjacent vascular-bioregulator layer.
Inflammation isn't just something to suppress — peptides like ARA-290 and KPV suggest you can reprogram the response entirely.
A plain-English look at the peptides being investigated for inflammation and tissue repair — what the evidence shows, what's still missing, and where the safety line sits.
Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.
Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.
Peptide-based gut healing splits across four mechanistically distinct compounds acting on different layers of the gastrointestinal barrier. The animal dossier is extensive; the human evidence is sparse; the regulatory posture is sceptical. An honest map of what is known, what is guessed, and where the practical safety decisions actually are.
BPC-157 drives angiogenesis and tissue repair. Larazotide antagonises zonulin to re-seal tight junctions. KPV suppresses NF-κB-driven inflammation. LL-37 reinforces the antimicrobial and mucus defence. The mechanism map is coherent. The human trial record — Larazotide's discontinued Phase III, BPC-157's three small pilots, the FDA's Category 2 classification — is sobering. Grey-market sourcing, not the peptides themselves, is the dominant source of documented harm.
GLP-1 agonists became a cultural phenomenon because they deliver dramatic short-term weight loss. The honest framing is chronic-disease pharmacology — effective while taken, compensation when withdrawn, best used alongside the nutritional foundation the drug amplifies.
Peptide-based appetite suppression splits across four classes — incretin agonists (semaglutide, tirzepatide, retatrutide), amylin analogs (cagrilintide), hypothalamic peptides (BRP), and growth-hormone fragments (AOD-9604). The multi-pathway arms race is producing larger weight losses, the weight-regain-on-discontinuation pattern is producing harder questions, and the nutritional foundation is producing the difference between therapeutic weight loss and iatrogenic frailty.
GLP-1 agonism is the headline. The full picture is three distinct peptide classes acting on glucose metabolism through three different mechanisms — and the honest protocol leads with the one that has actually passed regulatory scrutiny.
The peptide approach to blood sugar regulation splits into three distinct classes — incretin receptor agonists (GLP-1, dual GLP-1/GIP), mitochondrial-derived peptides (MOTS-c), and Khavinson bioregulators (Pankragen). Each sits on a different shelf of the evidence stack, each has a different risk profile, and the most common protocol error is treating them as interchangeable.
Sleep is not a pause — it is the most active regenerative state your biology runs. The peptides here tune its architecture without sedating the system.
Most sleep aids work by suppressing the central nervous system. A small class of peptides — DSIP, Epitalon, and the CJC-1295 / Ipamorelin stack — take the opposite approach: they restore the body's own sleep rhythms, hormonal pulses, and cellular repair cycles. This is sleep as biological fine-tuning, not sedation.
An evidence-based map of synthetic glyprolines — Selank, Semax, NPY and Pinealon — peptides engineered to modulate the HPA axis and amygdala reactivity without the sedation, dependence or cognitive blunting of benzodiazepines.
A rigorous look at the neuropeptide approach to modern stress: the Pro-Gly-Pro stability trick, the GABAergic-but-not-sedative mechanism of Selank, Semax's ACTH-derived neuroprotection, the Russian clinical evidence base, and the FDA Category 2 constraint that defines legal reality in the US.